GenIP plc
("GenIP" or the "Company")
Commercial Update
GenIP plc (AIM: GNIP), a provider of AI-driven services to help research organisations and corporations commercialise their innovations, provides an update on the soft launch of its Invention Evaluator Platform (the “Platform”) as announced on the 19 October 2026.
Successful Soft Launch
Several customers have now successfully trialled the Platform and initial feedback has been positive, with customers preferring the Platform’s new features and its streamlined, action-oriented approach to managing and prioritising technologies.
During the trial, the Company identified 17 pilot accounts across several international markets and has already begun initial commercial discussions about migrating them to the new Platform including a significant customer from 2025, who has already agreed to initiate the migration plan as an early adopter.
Based on this early feedback, management believes the pilot accounts alone could represent a potential annual subscription value of around US$170,000 in aggregate*.
Full Commercial Launch Remains on Track
The full commercial launch of the subscription-based Invention Evaluation Platform remains on track for December 2026.
Following the full commercial launch, the Company intends to target its historical customer base of approximately 300 customers presenting them the migration path to the subscription model.
Given the early feedback and ongoing customer conversations, management now estimates a global total addressable market of approximately US$50million per annum*, before additional services, for the new subscription Invention Evaluation Platform.
Continued commercial progress and sales pipeline
GenIP continues to secure orders for its existing services from new and existing customers, including universities in Chile and Brazil, a Brazilian technology company and a Spanish university-industry collaboration network:
- Following the appointment of a sales representative in Chile, GenIP has secured three new customers and reactivated two historical customer relationships across South America.
- Increased broader client adoption and repeat usage across academia, government innovation bodies and corporate Research and Development departments, diversifying and strengthening the customer base.
- Expanded commercial coverage across Asia and Latin America through regional business development appointments.
There is also growing engagement from commercial and corporate customers, including opportunities with organisations associated with Saudi Aramco and several advanced proposal discussions with Amazon Web Services (AWS) in Brazil.
In aggregate, management estimate these potential customers represent a sales pipeline of approximately US$1.0 million*.
Outlook
GenIP is entering a new commercial phase, with early positive interest from customers for the Invention Evaluator Platform with its more efficient operating model.
The Company’s immediate priorities are now to convert the significant and increasing sales pipeline into confirmed orders, secure its first paid platform subscriptions and demonstrate improved delivery margins.
The Board therefore remains confident the business will continue to trade in-line with management expectations for the remainder of 2026 and reduce cash burn by approximately 40% in 2027, as the businesses transitions onto a stronger foundation with significant levels of recurring revenue.
* Potential value is not contracted ARR or a revenue forecast.
GenIP plc Melissa Cruz, CEO | Via Walbrook PR |
Beaumont Cornish Limited (Nominated Adviser) Roland Cornish / Asia Szusciak / Andrew Price | Tel: +44 (0) 20 7628 3396 |
AlbR Capital Limited (Joint Broker) Colin Rowbury / Jon Belliss | Tel: +44 (0) 20 7399 9427 cr@albrcapital.com / Jb@albrcapital.com |
Walbrook PR (Financial PR) Alice Woodings William Turner | GenIP@walbrookpr.com Tel: +44 (0) 7407 804 654 Tel: +44 (0) 7407 020 470 |
focusIR (Investor Relations) Kat Perez Dr Paul Cornelius | GenIP@focusIR.com Tel: +44 (0) 20 4570 2234 Tel: +44 (0) 20 4570 2246 |
Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.
Distribution: This announcement has been notified via a Regulatory Information Service and it is not authorised for distribution into North America or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of that jurisdiction.
About GenIP
GenIP is a next-generation business at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.
Service Offerings
GenIP operates through two synergistic service lines:
Service | Description | Value Proposition |
Invention Intelligence Product Suite | AI-powered market intelligence reports assessing the commercial potential of emerging technologies | Enables faster, evidence-based decisions on R&D prioritisation, investment, and IP strategy |
IP Commercialisation Services | End-to-end engagement to help research organisations commercialise innovations | Provides cost-effective, broad support to achieve our clients' strategic objectives |
Together, these services form a unified GenAI-enabled platform for innovation triage and execution.
Vision & Strategy
GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:
- Organic Expansion: Scale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.
- Service Deepening: Enhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.
- Strategic Acquisitions: Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
